J&J squares up to Big Pharma rivals with extra RSV vaccine data

With GlaxoSmithKline, Pfizer and others in the running, Johnson & Johnson may need excellent data to capture the RSV vaccine market. The Big Pharma gave a further show of its credentials on Tuesday by sharing additional data from a study of thousands of seniors.

J&J shared top-line findings from the phase 2b clinical trial two months ago, revealing it hit its primary endpoint by linking the vaccine to 80% efficacy against confirmed RSV-associated lower respiratory tract disease. At that time, J&J also said the vaccine demonstrated 70% efficacy against any symptomatic RSV-associated acute respiratory infection.